Cloning, expression and pharmacological characterization of rabbit adenosine A1 and A3 receptors.

The role of adenosine A1 and A3 receptors in mediating cardioprotection has been studied predominantly in rabbits, yet the pharmacological characteristics of rabbit adenosine A1 and A3 receptor subtypes are unknown. Thus, the rabbit adenosine A3 receptor was cloned and expressed, and its pharmacology was compared with that of cloned adenosine A1 receptors. Stable transfection of rabbit A1 or A3 cDNAs in Chinese hamster ovary-K1 cells resulted in high levels of expression of each of the receptors, as demonstrated by high-affinity binding of the A1/A3 adenosine receptor agonist N6-(4-amino-3-[125I]iodobenzyl)adenosine (125I-ABA). For both receptors, binding of 125I-ABA was inhibited by the GTP analog 5'-guanylimidodiphosphate, and forskolin-stimulated cyclic AMP accumulation was inhibited by the adenosine receptor agonist (R)-phenylisopropyladenosine. The rank orders of potency of adenosine receptor agonists for inhibition of 125I-ABA binding were as follows: rabbit A1, N6-cyclopentyladenosine = (R)-phenylisopropyladenosine > N-ethylcarboxamidoadenosine > or = I-ABA > or = N6-2-(4-aminophenyl) ethyladenosine > > N6-(3-iodobenzyl)adenosine-5'-N-methyluronamide > N6-(4-amino-3-benzyl)adenosine; rabbit A3, N6-(3-iodobenzyl)adenosine-5'-N-methyluronamide > or = I-ABA > > N-ethylcarboxamidoadenosine > N6-2-(4-aminophenyl) ethyladenosine = N6-cyclopentyladenosine = (R)-phenylisopropyladenosine > N6-(4-amino-3-benzyl)adenosine. The adenosine receptor antagonist rank orders were as follow: rabbit A1, 8-cyclopentyl-1,3-dipropylxanthine > 1,3- dipropyl-8-(4-acrylate)phenylxanthine > or = xanthine amine congener > > 8-(p-sulfophenyl)theophylline; rabbit A3, xanthine amine congener > 1,3-dipropyl-8-(4-acrylate)phenylxanthine > or = 8-cyclopentyl-1,3-dipropylxanthine > > 8-(p-sulfophenyl)theophylline. These observations confirm the identity of the expressed proteins as A1 and A3 receptors. The results will facilitate further in-depth studies of the roles of A1 and A3 receptors in adenosine-mediated cardioprotection in rabbits, which can now be based on the appropriate recombinant rabbit A1 and A3 receptor pharmacology.

Purification and properties of a soluble angiotensin II-binding protein from rabbit liver.

An angiotensin II-binding activity has been purified almost 3,000-fold to a nearly homogenous state from the 100,000 x g supernatant fraction of rabbit liver. The responsible protein is apparently monomeric since its molecular weight was estimated to be 75,000 in the native state by glycerol gradient centrifugation and in the reduced, denatured state by gel electrophoresis. The Kd and Bmax values of the purified preparation were 7.2 nM and 15.2 nmol of angiotensin II bound per mg of protein, the latter figure agreeing well with the theoretical value of 13.3. Competition experiments with 125I-angiotensin II and unlabeled peptides revealed that the angiotensin antagonist [Sar1,Ala8]angiotensin II (saralasin) and the agonist [des-Asp1]angiotensin II (angiotensin III) were more tightly bound than angiotensin II, whereas angiotensin I and the carboxyl-terminal hexapeptide were less avidly bound. The cardiac peptide, atrial natriuretic factor, also competed for binding to the purified preparation but was about 15-fold less effective than angiotensin II. Although the binding activity was purified in the absence of detergent, a requirement for detergent in the binding reaction emerged during the isolation procedure. Binding by the purified protein exhibited an almost complete dependence upon the presence of detergent, p-chloromercuriphenylsulfonic acid and EDTA.

Antiserum to angiotensin-binding protein inhibits vascular responses to angiotensin II.

This study characterizes inhibitory properties of an antiserum to an angiotensin-binding protein on vascular responses to angiotensin II. The antiserum was collected from guinea pigs that had been immunized with an angiotensin-binding protein that was isolated from a particulate fraction of rabbit liver. The bioassay system consisted of helically cut strips of rabbit renal artery suspended in organ chambers for measurement of isometric force development. After treatment with the antiserum (1:1,000-1:50 dilution), contractile responses to angiotensin II (10(-8) M) were reduced compared with those measured after treatment with nonimmune serum. At a dilution of 1:50, the magnitude of contractile responses to angiotensin II were approximately 40% of control values. This inhibitory action of the antiserum was similar to that induced by the angiotensin II antagonist, saralasin. Contractile responses to norepinephrine (5.9 x 10(-8) M) were not altered after incubation with the antiserum. These results indicate that the binding protein in hepatic cells may be similar in some respects to the membrane receptor mediating contractions to angiotensin II in rabbit renal arteries.

Biochemical and immunological similarity of soluble angiotensin II-binding proteins in different organs.

Binding of angiotensin II has been detected in soluble extracts of rabbit liver, adrenal gland, aorta, brain, kidney and uterus. In each case, binding required p-chloromercuriphenylsulfonic acid and bound angiotensin II was released by treatment with dithiothreitol. These properties resemble those of the 75 kDa binding protein purified from liver. Immobilized guinea pig antiserum developed against the isolated hepatic protein removed binding activities from the different extracts in an immune-specific, quantitatively comparable manner. In addition, the activities were removed by a mouse monoclonal antibody which specifically recognized a protein of 75 kDa in the various preparations. An immunologically homologous angiotensin II-binding protein with similar characteristics was also identified in the soluble fraction of rat liver.

Purification and properties of an angiotensin-binding protein from rabbit liver particles.

An angiotensin II-binding protein was purified more than 8000-fold after solubilization from rabbit liver particles with digitonin. The procedure comprised fractionation with ammonium sulfate, chromatography on DEAE-cellulose and Affi-Gel 501, gel filtration through Sephacryl S-200, and chromatography with hydroxylapatite. The purified preparation exhibited Kd and Bmax values of 6.7 nM and 8.4 nmol of angiotensin II bound/mg protein. The latter figure represents more than 60% of the theoretical value calculated for a protein of Mr 75,000 as estimated for the major protein component by gel electrophoresis. The purified preparation displayed comparable or slightly higher affinities for various angiotensin antagonists and angiotensin III than that for angiotensin II, whereas angiotensin I as well as the hexapeptide and smaller carboxy-terminal fragments were less tightly bound. Binding of angiotensin II by the isolated protein was highly dependent upon the presence of p-chloromercuriphenylsulfonic acid and also required ethylene diaminetetraacetic acid which could be almost completely replaced by ethylene glycol bis(beta-aminoethyl ether) N,N'-tetraacetic acid but not by o-phenanthroline.

A soluble angiotensin II-binding protein from rabbit liver.

An angiotensin II-binding activity has been detected in the 100,000 x g supernatant fraction of rabbit liver. The total amount of binding activity in this fraction was substantially greater than that which could be solubilized from hepatic particles by treatment with digitonin. The crude soluble binding activity resembled the binding protein which had been purified from the particles in several respects. First, binding required the presence of p-chloromercuriphenylsulfonic acid and bound angiotensin II was released by dithiothreitol. Second, the molecular weight of the responsible protein cross-linked to radioiodinated angiotensin II was about 75,000 in the reduced, denatured state. Finally, guinea pig antiserum raised against the binding protein that had been purified from particles reacted identically with the soluble and solubilized activities.